While subretinal administration was generally tolerated, the observation that approximately one-quarter of participants developed increased RPE atrophy raises important safety concerns and highlights the need for further refinement of ABCA4 delivery approaches [33]. This evidence concerns the gene ABCA4 and Atrophy.